Balstilimab is under clinical development by Agenus and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase II drugs for Pleomorphic Liposarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Balstilimab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Balstilimab overview
AGEN-2034 (balstilimab) is under development for the treatment of metastatic angiosarcoma, metastatic soft tissue sarcomas, metastatic or locally advanced solid tumors including glioblastoma multiforme, ovarian cancer, advanced cutaneous squamous cell carcinoma, oropharyngeal cancer and non-small cell lung carcinoma, metastatic colorectal cancer, Hodgkin lymphoma, synovial sarcoma, peripheral nerve sheath tumor (neurofibrosarcoma), myxoid liposarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, round cell liposarcoma, leiomyosarcoma, fibrosarcoma, primary mediastinal B-cell lymphoma, endometrial cancer, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, gastric cancer, breast cancer, prostate cancer, bladder cancer, head & neck SCC, sarcoma and pancreatic cancer. The therapeutic candidate is administered intravenously. The drug candidate is checkpoint modulator antibody acts by antagonizing the programmed death-1 (PD-1, CD279). It is profiled based on retrocyte display technology and secant yeast display platform.
It was under development for the treatment of cervical cancer.
Agenus overview
Agenus is a biotechnology company. It is advancing therapies targeting cancer through a pipeline of immunological agents. The company’s portfolio includes several advanced platforms and programs designed to drive innovation in immuno-oncology (I-O). These consist of multiple proprietary antibody discovery platforms; antibody candidate programs such as botensilimab and balstilimab; a saponin-based vaccine adjuvant platform centered around the STIMULON cultured plant cell (CPC) QS-21 adjuvant and a pipeline of novel allogeneic invariant natural killer T (iNKT) cell therapies for treating cancer and other immune-mediated diseases. Agenus is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Balstilimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
